First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.
Rubius shows the first hints of clinical anticancer activity, and is suddenly worth $2.4bn.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.